EPICENTRX
DEAD

Serial Number

90796010

Owner

EpicentRx, Inc.

Attorney

Muzamil Huq

Filing Date

Jun 25, 2021

Add to watchlist:

No watchlists yet
View on USPTO

EPICENTRX Trademark

Serial Number: 90796010

EPICENTRX is a trademark filed by EpicentRx, Inc. on June 25, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

EpicentRx, Inc. (3 trademarks)

11099 North Torrey Pines Road, Suite 160
La Jolla, CA 92037

Entity Type: 03

Trademark Details

Filing Date

June 25, 2021

Registration Date

Not Registered

Published for Opposition

November 8, 2022

Goods & Services

Scientific and medical research and development in the fields of pharmaceuticals, biologics, agriculture, pest control, biotechnology, immunotherapies, and vaccines

Pharmaceutical products, preparations, and substances for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; biological products, preparations, and substances being medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; immunotherapies in the nature of medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; vaccines; pharmaceuticals in the nature of biotechnology platform technology, namely, viral and vaccine vectors for delivery and insertion of function-altering genetic material into human and animal patients, plants, and crops, for visualization of specific cell types, for inducing humoral and cell-mediated responses, for targeting and killing cancer cells, for removing pathological functions, for controlling biological pests, and for boosting crop yields; chemical platform technology, namely, small molecule compounds being pharmaceuticals for inducing the expression of antioxidant, anti-inflammatory, and cytoprotective proteins in non-malignant tissues, for activating the immune system, for modulating blood flow in ischemic tissues, for upregulating proinflammatory mediators in tumors, and for treating plant diseases

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Feb 2, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Feb 2, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 12, 2025 EXRA
SOU EXTENSION 5 GRANTED
Dec 11, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 11, 2025 AITU
SOU TEAS EXTENSION RECEIVED
Jul 1, 2025 EEXT
SOU EXTENSION 5 FILED
Jun 30, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 4 GRANTED
Jan 4, 2025 EX4G
SOU EXTENSION 4 FILED
Jan 4, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jan 3, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 2, 2024 EXRA
SOU EXTENSION 3 GRANTED
Jul 2, 2024 EX3G
SOU EXTENSION 3 FILED
Jul 2, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 2, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 5, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jan 3, 2024 EX2G
SOU EXTENSION 2 FILED
Jan 3, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 3, 2024 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 22, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 22, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 22, 2023 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 5, 2023 EXRA
SOU EXTENSION 1 GRANTED
Jul 3, 2023 EX1G
SOU EXTENSION 1 FILED
Jul 3, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 3, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 3, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 8, 2022 NPUB
PUBLISHED FOR OPPOSITION
Nov 8, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 19, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 3, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 23, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 22, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 22, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 22, 2022 GNRN
NON-FINAL ACTION E-MAILED
Mar 22, 2022 GNRT
NON-FINAL ACTION WRITTEN
Mar 22, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 16, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 9, 2021 NWOS
NEW APPLICATION ENTERED
Jun 29, 2021 NWAP